Medtronic’s Diabetes Management Business MiniMed Files for IPO

Company Overview - MiniMed Group Inc. is a diabetes management firm that is set to separate from Medtronic Plc and has filed for an initial public offering (IPO) [1][4] - The company has been part of Medtronic for nearly 25 years and offers a full ecosystem of automated insulin pumps, continuous glucose monitors, and smart insulin pens [3] Financial Performance - For the six months ended October 24, MiniMed reported a net loss of $21 million on revenue of $1.5 billion, an improvement from a net loss of $23 million on revenue of $1.3 billion in the same period the previous year [2] - The company generated approximately $2.7 billion in annual revenue for fiscal year 2025, with recent double-digit percentage growth [3] IPO Details - The IPO filing positions MiniMed to potentially debut in early 2026, alongside other companies such as EquipmentShare.com Inc. and Arko Petroleum Corp. [2] - Goldman Sachs Group Inc., Bank of America Corp., Citigroup Inc., and Morgan Stanley are leading the offering, with shares expected to trade on the Nasdaq Global Select Market under the symbol MMED [5] Corporate Structure and Future Plans - Medtronic will retain at least 80.1% of the voting power post-separation, and plans to distribute shares to investors in a tax-efficient manner, potentially as a spin-off [4] - MiniMed intends to use part of the IPO proceeds to repay intercompany debt owed to Medtronic [4]